Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00272844 · ClinicalTrials.gov registry record · Phase 1
Treatment of the Cholesterol Defect in Smith-Lemli-Opitz Syndrome
A Phase 1 study, sponsored by Boston Children's Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT00272844 is a Phase 1 study that has completed, run by Boston Children's Hospital. The registered enrollment target is 23 participants.
The verdict
NCT00272844, a Phase 1 study, has completed, sponsored by Boston Children's Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether supplementation with an oil-based cholesterol suspension will correct the biochemical abnormalities in cholesterol and its precursors in individuals with the Smith-Lemli-Opitz syndrome.
Interventions
- DRUG crystalline cholesterol oil-based suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 1998-01 |
| Est. Completion | 2011-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00272844
The ClinicalTrials.gov registry entry for NCT00272844 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which crystalline cholesterol oil-based suspension is the first listed.
NCT00272844 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00272844 about?
NCT00272844 is a clinical study titled "Treatment of the Cholesterol Defect in Smith-Lemli-Opitz Syndrome". The purpose of this study is to determine whether supplementation with an oil-based cholesterol suspension will correct the biochemical abnormalities in cholesterol and its precursors in individuals with the Smith-Lemli-Opitz syndrome.
What is the current status of trial NCT00272844?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 1998-01. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00272844?
The interventions under investigation include: crystalline cholesterol oil-based suspension (DRUG).
Who is sponsoring clinical trial NCT00272844?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.